EGFR UNCOMMON MUTATIONS

Clinical trials for EGFR UNCOMMON MUTATIONS explained in plain language.

Never miss a new study

Get alerted when new EGFR UNCOMMON MUTATIONS trials appear

Sign up with your email to follow new studies for EGFR UNCOMMON MUTATIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

Global race for better lung cancer treatment targets rare mutations

Disease control Recruiting now

This global Phase 3 trial is comparing a new drug called firmonertinib against two existing standard treatments for people with advanced non-small cell lung cancer that has specific, less common EGFR genetic mutations. The study aims to see if firmonertinib can better control the…

Matched conditions: EGFR UNCOMMON MUTATIONS

Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

EGFR UNCOMMON MUTATIONS

Get alerted when new EGFR UNCOMMON MUTATIONS trials appear

Global race for better lung cancer treatment targets rare mutations